Latest filing published 10 Aug 2026 for Dianthus Therapeutics, Inc., €1.5M.
Insider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
Adam Veness: trading record in brief
Adam Veness is a declared insider of Dianthus Therapeutics, Inc. /DE/, with filings sourced from SEC (Form 4). We count 2 filings; the first trade dates from 7 August 2026 and the latest from 10 August 2026.
None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Because grants and exercises are largely decided by remuneration plans, they are not counted as purchases here.
Most recently, on 10 August 2026, the filings show a transaction worth €1.5M in Dianthus Therapeutics, Inc. /DE/. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Adam Veness
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 16,167 shares@ US$108.92CommonSEC144:0001950047-26-007911
- 3,833 shares@ US$109.920.0067% mcap100.0% of flowCommonSEC144:0001950047-26-007811
2 of 2 declarations
